The purpose of the Administration, Evaluation, and Planning Core is to ensure the coordination of the Dana-Farber/Harvard Cancer Center (DF/HCC) Prostate Cancer SPORE components and to provide oversightand leadership of the scientific, administrative, and fiscal aspects of the SPORE.Within the DF/HCC Prostate Cancer SPORE, there are several layers of oversight and evaluation. Dr.Kantoff, as SPORE Director, monitors the progress of the Projects and Cores and oversees the CareerDevelopment Program (along with Drs.Sanda and D'Amico), the Developmental Projects Program (alongwith Drs.Cantley and Stampfer), and all other proposed activities. Within the DF/HCC, Dr. Kantoff has theauthority and resources to ensure the success of this SPORE. Our Governance Committee, made up ofsenior members of the DF/HCC Prostate Cancer Program, meet monthly to provide immediate decision-making. We have two strong Co-Pis. Dr. Kantoff will be joined by Lewis Cantley, PhD, Professor of SystemsBiology and Chief, Division of Signal Transduction at the Beth Israel Deaconess Medical Center, to assumethe responsibility as Co-Pi of the SPORE. Dr. Cantley, a member of the National Academy since 2001 andthe PI of a PO1 on signal transduction in prostate cancer, brings outstanding basic science expertise to ourProgram and SPORE. Meir Stampfer, MD, Dr.P.H., Professor of Nutrition and Epidemiology, Chair,Department of Epidemiology, Harvard School of Public Health, will also serve as Co-Pi. Given Dr. Stampfer'sinterest and expertise in prostate cancer and the centrality of population science in this SPORE application,his leadership is welcome. We have a strong Internal Advisory Board, comprised of prominent members ofthe Harvard Medical School community and representing the participating institutions and major cancerresearch disciplines. Our External Advisory Board will meet in the Boston area annually during the five-yearfunding cycle. The membership and functions of these committees are discussed in detail in the descriptionof this Core.The Administration, Evaluation, and Planning Core allows for the provision of stimulating intellectualactivities, organization of venues for planning future research through seminars and retreats, and theoversight of research and spending. This Core also provides the tools to work with institutions inside andoutside of Harvard University to leverage the considerable power of the SPORE in order to raise moreresearch funding for prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA090381-06
Application #
7314583
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
6
Fiscal Year
2007
Total Cost
$502,387
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Dickerman, Barbra A; Torfadottir, Johanna E; Valdimarsdottir, Unnur A et al. (2018) Midlife metabolic factors and prostate cancer risk in later life. Int J Cancer 142:1166-1173
McKay, Rana R; Werner, Lillian; Jacobus, Susanna J et al. (2018) A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer :
Larimer, Benjamin M; Bloch, Emily G; Nesti, Sarah et al. (2018) The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. Clin Cancer Res :
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917
Chen, Sen; Cai, Changmeng; Sowalsky, Adam G et al. (2018) BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Res 78:5203-5215
Pakula, Hubert; Linn, Douglas E; Schmidt, Daniel R et al. (2018) Protocols for Studies on TMPRSS2/ERG in Prostate Cancer. Methods Mol Biol 1786:131-151
Elfandy, Habiba; Armenia, Joshua; Pederzoli, Filippo et al. (2018) Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res :
Han, W; Gao, S; Barrett, D et al. (2018) Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. Oncogene 37:710-721
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233
Russo, Joshua W; Liu, Xiaming; Ye, Huihui et al. (2018) Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett 438:97-104

Showing the most recent 10 out of 261 publications